Accès ouvert
2024
article
OpenAlex
Simon Valayer, Marie Alexandre, Mélanie Prague, Abdoul Habib Béavogui et autres
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination.Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to …
fr, Mali, Guinée, Libéria, gb, Sierra Leone, us, lu, de, Sénégal, Bénin, nl
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Aurélie Wiedemann, Édouard Lhomme, Mélanie Huchon, Emile Foucat et autres
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized trial (NCT02876328), we report the results of …
fr, Sénégal, us, gb, Sierra Leone, Libéria, nl, Mali
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Andrew W. Lee, Ken Liu, Édouard Lhomme, Julie Blie et autres
BACKGROUND: The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine indicated for the prevention of Ebola virus disease (EVD) caused by Zaire ebolavirus in individuals 12 months of age and older. METHODS: The Partnership for Research on Ebola …
us, fr, Libéria, Mali, Sierra Leone, gb, Tanzanie
(code pays fourni par la source)